{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123279","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.518142+00:00","generated_at":"2026-05-30T03:41:42.844572+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches","bullets":["Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.","Net loss $16.2M ($0.62 loss per share) vs $8.7M loss in prior year quarter.","Amended OrbiMed credit agreement: terminated two $50M tranches, removed Q4 2024 revenue covenant.","Full-year 2024 revenue guidance reaffirmed at $68-70M (37-41% growth); Q4 guidance $22.3-24.3M.","Expects RECELL GO mini FDA approval by Dec 31, 2024; Cohealyx launch Jan 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123279","json":"https://secwatch.observer/filing/0000950170-24-123279.json","markdown":"https://secwatch.observer/filing/0000950170-24-123279.md","text":"https://secwatch.observer/filing/0000950170-24-123279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024123279/0000950170-24-123279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017024123279/rcel-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:41:42.844572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}